Discovery of cancer gene may predict survival in patients with mouth cancers

May 4, 2016, Loyola University Health System
Michael J. Zilliox, PhD, director of the Loyola Genomics Facility and lab manager Gina Kuffel. Credit: Loyola University Chicago

Loyola researchers have identified a tumor gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue.

If the gene is expressed (turned on), patients are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.

The finding, published in the journal Otolaryngology - Head and Neck Surgery, could help guide treatment, researchers say. If the is expressed, a patient may require more aggressive treatment, such as radiation and possibly chemotherapy in addition to surgery. Conversely, if the gene is unexpressed (turned off), the patient might be able to safely forgo and undergo surgery alone.

The Gene Expression Barcode, a research tool co-invented by Michael J. Zilliox, PhD, was used to examine genetic data from 54 patients with . Zilliox is corresponding author of the study, director of the Loyola Genomics Facility and an assistant professor in Loyola Stritch School of Medicine and Graduate School's department of public health sciences.

The study involved a type of mouth cancer called . Physicians estimate survival based on the stage of the disease. Staging is based on factors including the size of the tumor and whether it has spread to nearby lymph nodes or other organs.

But staging provides an imprecise estimate of prognosis. In some cases, patients with early-stage disease can have worse outcomes than patients with later-stage disease. Previous studies have found that patients with oropharynx cancers associated with the human papillomavirus (HPV) tend to have better outcomes. But there is no reliable biomarker to predict outcomes among patients who are HPV negative, said Carol Bier-Laning, MD, a Loyola head-and-neck cancer surgeon and co-author of the study. Dr. Bier-Laning is an associate professor in Stritch School of Medicine's department of otolaryngology.

Using the Gene Expression Barcode, researchers examined publically available genetic data from 54 tumor samples. The samples were taken from patients who had HPV-negative squamous cell carcinoma in the mouth.

The study found that subjects whose tumors expressed a gene called spectrin were 4.6 times more likely to die at any given time when compared with patients without spectrin. (Spectrin is a gene involved in the formation of cell membranes.)

Even when researchers controlled for cancer stage and other factors, patients with the expressed spectrin gene still were significantly more likely to die than those in which the gene was turned off. This finding suggests that the spectrin gene may provide more information about survival than cancer stage alone.

The researchers caution the results are preliminary and need to be validated in an independent patient group. Such research is ongoing.

Research institutions have made public from nearly 100,000 , most of whom had . In raw form, however, these data are too unwieldy to be of much practical use for most researchers. The Gene Expression Barcode applies advanced statistical techniques to make the mass of data much more user-friendly to researchers.

The barcode algorithm is designed to estimate which genes are expressed and which are unexpressed. Like a supermarket barcode, the Gene Expression Barcode is binary, meaning it consists of ones and zeroes - the expressed genes are ones and the unexpressed are zeros.

Explore further: Helping cancer researchers make sense of the deluge of genetic data

More information: S. F. Yang et al, Candidate Biomarkers for HPV-Negative Head and Neck Cancer Identified via Gene Expression Barcode Analysis, Otolaryngology—Head and Neck Surgery (2016). DOI: 10.1177/0194599816642436

Related Stories

Helping cancer researchers make sense of the deluge of genetic data

December 12, 2013
A newly improved internet research tool is helping cancer researchers and physicians make sense out of a deluge of genetic data from nearly 100,000 patients and more than 50,000 mice.

Study suggests improvements in how mesothelioma is staged

February 2, 2016
A new study suggests that significant improvements could be made in the scoring system physicians use to estimate the stage (severity) of mesothelioma, an aggressive and deadly cancer.

Biomarker predicts which stage II colon cancer patients may benefit from chemotherapy

January 20, 2016
A multicenter research team has identified a biomarker that predicts which stage II colon cancer patients may benefit from chemotherapy after surgery to prevent a recurrence of their disease.

Specific gene in the tumor determines the effectiveness of cancer treatment

April 14, 2016
A cancer treatment can be basically effective but, equally, it may have negative consequences. Hitherto, it has not been possible to determine prior to treatment whether a patient will benefit from standard cancer treatment ...

Cancer-causing gene found in plasma may help predict outcomes for patients

February 18, 2016
Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person's immune ...

Study uncovers genetic differences for kidney cancer that may contribute to survival disparity in African-Americans

March 30, 2016
A University of North Carolina Lineberger Comprehensive Cancer Center-led study has identified genetic differences in tumors of African-Americans with the most common type of kidney cancer compared with whites.

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.